NanoViricides Inc. (NNVC)

[FORZANANO]

WEST HAVEN, Conn., Jan. 21, 2015 /PRNewswire/ -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"), reported that between January 6 and 13, 2015, Anil Diwan, PhD, the Company's co-founder, President and Chairman, and Dr. Milton Boniuk, an independent member of the Board of Directors, separately purchased NanoViricides common stock in open market purchases, during one of the Company's open trading windows for insiders.

The insider purchases were reported on Form 4's with the Securities and Exchange Commission (SEC) and their combined purchases amounted to 62,392 shares of NanoViricides common stock in uncoordinated open market purchases. During one of the Company's open trading windows for insiders, Dr. Diwan purchased 37,392 shares and independently, Dr. Boniuk purchased 25,000 shares. Shares were purchased at the open market prices ranging between $2.54 and $2.75; prices that Dr. Diwan and Dr. Boniuk believe are a substantial discount to the Company's potential long term value.

For Dr. Diwan, the purchases were made using certain proceeds from the sale of the cGMP facility that was recently sold by Dr. Diwan's special purpose entity Inno-Haven, LLC to the Company, on a costs reimbursement basis, as reported previously. The original purchase of the building prior to extensive renovations was accomplished by Dr. Diwan using his personal savings, loans from other parties, and, in part, from the 10b5-1 sales of his founder shares of the Company's stock in 2011.

"Continuing purchases by insiders is a sign of confidence in the future of the Company," said Eugene Seymour, MD, MPH, Chief Executive Officer, "and reflects the on-going progress towards our goal of getting our drugs into humans as soon as possible."